

family members' health all increased significantly after COVID-19. Only a minority of African-Americans agreed they would get the needed healthcare if they contracted COVID-19. These findings have implications for the mental health and behavioral impacts of COVID-19 on African-Americans and for the development of health communications to high-disease-incidence populations.

Disclosures: All Authors: No reported disclosures

546. Capturing Clinician's Experiences Repurposing Drugs to Inform Future Studies During COVID-19

Mili Duggal, MPH, PhD¹; Heather Stone, MPH¹; Parvesh Paul, MBBS, MD²; Reema Charles, MBBS, MS³; Leonard Sacks, MD¹; Noel Southall, PhD²; FDA, Silver Spring, MD; ²NCATS/NIH, Silver Spring, Maryland

Session: P-21. COVID-19 Treatment

Background: CURE ID is an internet-based repository developed collaboratively by FDA and NCATS/NIH, with the support of WHO and IDSA. It encourages clinicians globally to share novel uses of existing drugs for patients with difficult-to-treat infections. It is designed to serve as a rapid communication platform for healthcare providers during an outbreak, providing for systematic case-sharing, discussion, and the latest literature. Besides case reports, CURE ID offers a discussion platform for clinicians, disease-specific clinical trials curated from clinicaltrials.gov, and a newsfeed that shows relevant journal articles and news related to COVID-19 and other infectious diseases.

Methods: The CURE ID team extracted individual case reports on patient-level treatments and outcomes of COVID-19 infection from the published literature and gathered clinician-submitted cases through the electronic case report form. Additionally, CURE ID partnered with the University of Pennsylvania's CORONA database to further populate the CURE ID database with published cases.

Results: As of submission, lopinavir-Ritonavir (n=51) was the most commonly reported drug used. The following were also reported: hydroxychloroquine (n=31), azithromycin (n=28), arbidol (n=22), interferon alfa-2B (n=18), moxifloxacin (n=18), methylprednisolone (n=17), ivermectin (n=14), lopinavir (n=12), oseltamivir (n=12). The other drugs reported were danoprevir-ritonavir, intravenous immunoglobulins, interferon, interferon alfa, and tocilizumab. CURE ID currently includes more than 150 detailed COVID case reports of 65 repurposed drugs. We expect case reporting for specific drugs to be dynamic and additional data to accrue. Updated results will be presented.

Conclusion: Several drugs are being repurposed to treat COVID-19. CURE ID gives clinicians an opportunity to share their treatment experiences and discuss their questions with a global community of healthcare providers. By utilizing the CURE ID platform, in conjunction with data gathered from other registries, observational studies and clinical trials, hypotheses can be generated that may inform future clinical trials and ultimately, potentially find safe and effective treatments for this deadly disease.

Disclosures: All Authors: No reported disclosures

547. A Retrospective Cohort Study of Treatment Patterns and Clinical Outcomes in Patients with COVID-19

Haley Pritchard, MD, MS¹; Jon Hiles, PharmD, BCPS-AQ ID²; Batteiger Teresa, MD¹; Armisha Desai, BCPS³; Justin E. Wrin, PharmD, BCPS, BCIDP⁴; Ariel Hlavaty, PharmD⁵; Amanda Agard, MD¹; Bradley Hinton, PharmD²; Christine W. Lucky, MD, MPH¹; Elizabeth Fleming, MD¹; Humaira Khan, MD¹; John P. Bomkamp, PharmD²; Jon Derringer, PharmD²; Jack Schneider, MD¹; Jonathan Ryder, MD¹; Jason D. Russ, MD¹; Haseeba Khan, MD¹; Svetlana Kleyman, MD¹; Leslie A. Enane, MD, MSc¹; Matthew Stack, MD¹; Michelle L. Kussin, PharmD, BCOP²; Courtney Myers, MD¹; Allysa Nagy, MD¹; Noah Richardson, MD¹; Omar Elsheikh, MD¹; Omar Rahman, MBBS¹; Rachel Krueger, PharmD²; Russell Trigonis, MD¹; Saira Butt, MD¹; Samina Bhumbra, MD¹; Sasha Kapil, MD¹; Tanya Abi-Mansour, PharmD²; Zachary Howe, PharmD²; Wassim Abdallah, MD¹; Samir Gupta, MD¹; Kara Woos-Kaloustian, MD¹; ¹Indiana University School of Medicine, Indianapolis, Indiana; ²IU Health, Indianapolis, Indiana; ³Indiana University Health Adult Academic Health Center, Indianapolis, IN; ⁴Indiana University Health AHC, Indianapolis, Indiana

Session: P-21. COVID-19 Treatment

Background: The SARS-CoV-2 pandemic has caused over 400,000 deaths worldwide thus far, and poses therapeutic challenges for millions of patients. There is currently no treatment for SARS-CoV-2 infection approved by the United States Food and Drug Administration. Multiple agents have been used off-label to treat SARS-CoV-2 infection based on small observational cohorts and *in vitro* data. Here we present the experience of a large academic medical center in treating SARS-CoV-2 infection.

Methods: We performed a retrospective cohort study of patients admitted for greater than 24 hours with a nasopharyngeal, oropharyngeal, and/or bronchoalveolar lavage sample positive for SARS-CoV-2 by polymerase chain reaction (PCR). Demographic data, comorbidities, clinical data, and treatment data were collected from the electronic medical record. Off-label therapies were used at the discretion of the treating providers guided by regularly updated treatment guidelines assembled by infectious diseases physicians and antimicrobial stewardship pharmacists. The primary outcome assessed was in-hospital mortality. Secondary outcomes included admission

to the intensive care unit (ICU), endotracheal intubation, initiation of vasopressors, and drug-related adverse events.

Results: Data collection was completed for 448 patients admitted between March 18, 2020 and May 8, 2020. All-cause in-hospital mortality was 13.4% (60/448) during this time. Mortality rates increased with age, up to 45% for patients over 80 years old. Male sex, hypertension, chronic pulmonary disease, end-stage renal disease, chronic liver disease were also risk factors for increased mortality. QTc interval prolongation occurred significantly more frequently in patients who received hydroxychloroquine (HCQ) with or without azithromycin (AZM) than those who did not (HCQ 6%, HCQ+AZM 7.8% vs all other patients, 0%, p < .0001). Review of treatment trends showed close adherence to the treatment recommendations at that time (Figure 1).

Patient Characteristics

Demographics	
Age (years)	57.07 (19.53); 0 – 98
Height (cm)	168 (21.5 – 203)
Weight (kg)	88.95 (3.8 – 229.1)
Gender	
Female	210 (49.1)
Male	218 (50.9)
Treatment	
Hydroxychloroquine	84 (18.8)
Hydroxychloroquine + intentional Azithromycin	55 (12.3)
Hydroxychloroquine + empirical Azithromycin	60 (13.4)
Convalescent plasma	35 (7.8)
Tocilizumab	19 (4.2)
Remdesivir	26 (58.8)
IMAB study drug	4 (0.9)
Supportive Care Only	165 (36.8)
Severity Grade	
No supplemental O2, no ICU admission	86 (19.2)
Supplemental O2, no ICU admission	178 (39.7)
ICU admission < 48 hours after admission	61 (13.6)
ICU admission >= 48 hours after admission	32 (7.1)
Required vasopressors	91 (20.3)
Primary Outcome	
Disposition	
Alive	388 (86.6)
Dead	60 (13.4)
Secondary Outcomes	
Need for intubation	122 (27.2)
Need for ICU admission	183 (40.9)
Time from admit to intubation (days)	1 (0, 17)
Time from admit to ICU admission (days)	0 (0, 17)
Time intubated	10 (0, 49)
Time in ICU	9 (0, 50)
ECMO	8 (1.8)
Drug adverse events	46 (10.3)
QTc prolongation	14 (3.1)

Values are mean (standard deviation); range for age, median (range) for height, weight, and "time until" variables, and frequencies (percentages) for the categorical variables. Frequencies may not add to overall sample size due to missing data.

Admission Laboratory Data by Disease Severity

Lab value	No suppl O2, no ICU (n=86)	Suppl O2, no ICU (n=178)	ICU < 48 hrs after admission (n=61)	ICU >= 48 hrs after admission (n=32)	Vasopressors (n=91)	p-value
Fibrinogen (mg/dL)	405(359,488)	354(377,651)	538(465,615)	461(300,657.5)	528(438,632)	0.2247
Oxygen saturation (%)	97(95,99)	91(87,95)	87(76,92)	93(87,95)	87(70,91)	<.0001
White Blood Cell count (cells/mm ³)	6.3(4.7,8.6)	6.6(5.9)	8.4(6.05,10.6)	5.8(4.45,7.7)	7.3(5.1,11.9)	0.0002
Hemoglobin (g/dL)	12.8(11.7,13.6)	12.2(11.8,14.3)	13.5(12.25,14.55)	13.4(11.14,14.5)	13.35(11.24,14.7)	0.1591
Platelets (k/mm ³)	214(150,296)	194(151,267)	239.5(179,279)	191(121.5,233.5)	189(139,265)	0.0125
Lymphocyte (%)	19(12.29)	14(10.23)	12(7.19)	14(9.21)	10(7.16)	<.0001
D-dimer (ng/mL)	315(200,462)	338.5(241,499)	480(373,607)	301(200,595)	658(346,1049)	<.0001
Creatinine (mg/dL)	0.9(0.72,1.41)	1.03(0.79,1.45)	1.04(0.83,1.36)	1.1(0.94,1.72)	1.26(0.85,2.06)	0.0431
Alkaline phosphatase (Units/L)	70(55,94)	68(53,89)	76(57,95)	64(44,81)	64(47,5,84)	0.1835
Alanine aminotransferase (Units/L)	19(13,35)	25(15,41)	28(18,48)	31(21,56)	29.5(19,54.5)	0.0026
Aspartate aminotransferase (Units/L)	25.5(20,43)	36(24,48)	41(30,62)	36(28,61)	53.5(32,80)	<.0001
Hemoglobin A1C (%)	7.6(5.9,9.35)	7.8(6.7,9)	7.5(6.6,11.5)	7.2(6.65,8.4)	7.7(6.6,8.9)	0.9101
Lactate dehydrogenase (mg/dL)	272(218,355)	343(264,458)	459(315,558)	342(306,433)	440.5(337,591)	<.0001
Troponin (ng/mL)	0.09(0.03,0.03)	0.09(0.03,0.04)	0.09(0.03,0.05)	0.09(0.03,0.03)	0.05(0.03,0.15)	<.0001
Ferritin (ng/mL)	388.3(205.9,859.2)	418.4(207.5,808.7)	605.5(245,1146.3)	454.5(299.8,1062.3)	718.7(772.5,1262.85)	0.0099
C-reactive protein (mg/dL)	3.9(1.1,9)	7.1(3.5,14.3)	10(6.9,19.3)	8.2(3.1,13.1)	13.85(9.34,3)	<.0001
IL-6 (pg/mL)	5(5.5)	4(5.13)	12(5.32)	12(6.28)	15(7.41,9)	<.0001
Procalcitonin (ng/mL)	0.34(0.07,0.27)	0.17(0.1,0.45)	0.24(0.13,0.54)	0.15(0.1,0.35)	0.51(0.19,1.91)	<.0001

Values are medians (IQRs) with p-values from Kruskal-Wallis rank-sum tests, due to data skewness.

QTc Prolongation


	HCQ	HCQ+AZM	No HCQ or AZM	p-value
QTc prolongation	5 (6.0)	9 (7.8)	0 (0)	<.0001*
No QTc prolongation	79 (94.1)	106 (92.2)	249 (100)	

Values are frequencies (percentages) with p-value from Fisher's Exact test.


AZM, azithromycin; HCQ, hydroxychloroquine

Conclusion: SARS-CoV-2 infection is associated with significant inpatient mortality, and use of off-label treatments was associated with significant drug-related adverse events. Treatment regimens changed rapidly, and providers adhered closely to institutional guidelines as they evolved.

Treatment Trends by Week



QTC pre/post Treatment by Hydroxychloroquine Use vs. No Hydroxychloroquine Use



Disclosures: Samir Gupta, MD, Gilead Sciences (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member) Viiv (Consultant, Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Research Grant or Support)

548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19

Antonella Castagna, MD¹; David Shu Cheong Hui, MD²; Kathleen M. Mullane, DO, PharmD³; Kathleen M. Mullane, DO, PharmD³; Mamta Jain, MD⁴; Massimo Galli, MD⁵; Shan-Chwen Chang, MD, PhD⁶; Robert H. Hyland, MD⁷; Devi SenGupta, MD⁷; Huyen Cao, MD⁷; Hailin Huang, PhD⁷; Anand Chokkalingam, PhD⁸; Anu Osinusi, MD⁸; Diana M. Brainard, MD⁷; Christoph Lübbert, MD⁹; David Chien Boon Lye, MD¹⁰; David Chien Boon Lye, MD¹⁰; Judith A. Aberg, MD¹¹; Enrique Navas Elorza, MD¹²; Karen T. Tashima, MD¹³; Mark McPhail, MD¹⁴; ¹IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Lombardia, Italy; ²Chinese University of Hong Kong, Hong Kong, Not Applicable, Hong Kong; ³University of Chicago, Chicago, Illinois; ⁴UT Southwestern, Dallas, Texas; ⁵Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, ASST Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Lombardia, Italy; ⁶National Taiwan University Hospital, Taipei, Taipei, Taiwan (Republic of China); ⁷Gilead Sciences Inc., Foster City, California; ⁸Gilead, foster City, California; ⁹Klinikum St. Georg Klinik für Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Hessen, Germany; ¹⁰National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore; Not Applicable, Singapore; ¹¹Icahn School of Medicine at Mount Sinai, New York, New York; ¹²Hospital Universitario Ramon y Cajal, Madrid, Madrid, Spain; ¹³The Miriam Hospital, Providence, Rhode Island; ¹⁴King's College Hospital NHS Foundation Trust, London, England, United Kingdom

Session: P-21. COVID-19 Treatment

Background: Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Here we report baseline characteristics associated with clinical improvement at day (d) 14.

Methods: We enrolled hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation >94% on room air, and radiological evidence of pneumonia. Patients were randomized 1:1:1 to receive 5d or 10d of intravenous RDV once daily plus standard of care (SoC), or SoC only. For this analysis, patients were followed through discharge, d14, or death. Baseline demographic and disease characteristics associated with clinical improvement in oxygen support (≥2-point improvement on a 7-category ordinal scale ranging from discharge to death) were evaluated using multivariable logistic regression methods.

Results: 584 patients were randomized and treated (5/10d RDV, n=384; SoC: n=200). 159 (27%) were ≥65y, 227 (39%) female, 328 (61%) white, 102 (19%) Asian, and 99 (19%) Black. 252 participants (43%) were enrolled in Europe, 260 (45%) North America (NA), and 72 (12%) in Asia. Most patients (483 [83%]) were not on supplemental oxygen but required medical care at baseline. In a multivariable model, 5/10d RDV was significantly positively associated with clinical improvement (adjusted odds ratio [OR] 1.69, 95% CI: 1.08, 2.65; p=0.0226). Significant covariables positively associated with clinical improvement included age < 65y (p<0.0001) and region of treatment (Europe and NA vs Asia, p<0.0001 each; Table); other examined factors were not significantly associated with clinical improvement, including gender, race, ethnicity, baseline oxygen support, duration of symptoms and hospitalization, obesity, and baseline transaminase levels.

Table 1.

Table. Baseline characteristics associated with ≥2-point improvement at day 14 in patients with moderate COVID-19 treated with 5 days or 10 days remdesivir vs standard of care (based on multivariate analyses)

Risk factor: Subgroups	Univariate p-value	Multivariate p-value ^{a, b}	Multivariate OR (95% CI) ^a
Age: <65 vs ≥65y	0.0002	<0.0001	3.21 (2.03, 5.09)
Gender: Male vs Female	0.1504	NS	-
Ethnicity: Hispanic vs non-Hispanic	0.0154	NS	-
Race Black vs Asian	<0.0001	NS	-
White vs Asian	<0.0001	NS	-
Region: Europe vs Asia	<0.0001	<0.0001	26.56 (12.17- 57.94)
North America vs Asia	<0.0001	<0.0001	66.20 (29.15- 150.32)
Baseline oxygen: Room air vs low-flow/high-flow oxygen	0.6784	NS	-
Duration of hospitalization: ≤2 vs > 2d	0.0643	NS	-
Duration of symptoms: ≤10 vs >10d	0.7428	NS	-
Obesity: Y vs N	<0.0001	NS	-
Baseline ALT: >29 vs ≤29 U/L	0.6804	NS	-
Baseline AST: >33 vs ≤33U/L	0.6729	NS	-

^a Adjusted for treatment arm and other variables in the multivariate model.
^b NS: non-significant (not selected) at p<0.05

Conclusion: In moderate COVID-19 patients, after adjusting for treatment arm, age < 65y and region (NA vs Asia; Europe vs Asia) were associated with higher rates of clinical improvement. These observations recapitulate younger age as positive prognostic factor, and highlight the differences in the impact of the pandemic globally.

Disclosures: Antonella Castagna, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Shu Cheong Hui, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Kathleen M. Mullane, DO, PharmD, Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator) Mamta Jain, MD, Gilead Sciences Inc. (Scientific Research Study Investigator, Research Grant or Support) GlaxoSmithKline (Advisor or Review Panel member) Janssen (Research Grant or Support) Merck (Research Grant or Support) Massimo Galli, MD, Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Personal fees) Shan-Chwen Chang, MD, PhD, Gilead Sciences Inc. (Scientific Research Study Investigator) Robert H. Hyland, MD, Gilead Sciences Inc. (Employee, Shareholder) Devi SenGupta, MD, Gilead Sciences Inc. (Employee, Shareholder) Huyen Cao, MD, Gilead Sciences Inc. (Employee, Shareholder) Hailin Huang, PhD, Gilead Sciences Inc. (Employee, Shareholder) Anand Chokkalingam, PhD, Gilead Sciences (Employee) Anu Osinusi, MD, Gilead Sciences (Employee) Diana M. Brainard, MD, Gilead Sciences (Employee) Christoph Lübbert, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Chien Boon Lye, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Chien Boon Lye, MD, NO DISCLOSURE DATA Judith A. Aberg, MD, Theratechnology (Consultant) Enrique Navas Elorza, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Karen T. Tashima, MD, Bristol-Myers Squibb (Research Grant or Support) Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator) GlaxoSmithKline (Research Grant or Support) Merck (Research Grant or Support) Tibotec (Research Grant or Support) Viiv Healthcare (Research Grant or Support) Mark McPhail, MD, Gilead Sciences Inc. (Scientific Research Study Investigator)

549. Clinical Characteristics and Outcomes of Patients with COVID-19 treated with Convalescent Plasma in Miami, Florida

Shweta Anjan, MD¹; Dimitra Skiada, MD²; Miriam Andrea Duque Cuartas, MD³; Douglas Salguero, MD⁴; David P. Serota, MD MSc⁵; Jose Gonzales-Zamora, MD⁵; Folsukin Ayoade, MD³; Laura Beauchamps, MD, MD²; Tanya R. Quiroz, MSN, APRN, FNP-BC³; Jovanna Bertran-Lopez, MD²; Patricia Raccamarich; Emily K. Montgomerie, BS²; Irma Barreto, n/a²; Lilian M. Abbo, MD, FIDSA⁶; Lilian M. Abbo, MD, FIDSA⁶; Susanne Doblecki-Lewis, MD, MSPH⁷; Yanyun Wu, MD²; Maria L. Alcaide, MD²; ¹University of Miami / Jackson Memorial Hospital, Miami, Florida; ²University of Miami Miller School of Medicine, miami, Florida; ³University of Miami, Miami, Florida; ⁴University of Miami Miller School of Medicine, Miami, Florida; ⁵University of Miami, Miller School of Medicine, Miami, Florida; ⁶University of Miami Miller School of Medicine & Jackson Health System, Miami, Florida

Session: P-21. COVID-19 Treatment

Background: The Coronavirus disease of 2019 (COVID-19) global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in unprecedented mortality, impacted society, and strained healthcare systems, yet sufficient data regarding treatment options are lacking. Convalescent plasma, used since 1895 for infectious disease outbreaks, offers promise as a treatment option for COVID-19.

Methods: This is a retrospective study of patients diagnosed by a nasopharyngeal swab SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR), who received convalescent plasma between April to June 2020 at two large hospitals in Miami, Florida, as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma (CCP).

Results: A total of 23 patients received CCP, 13 (57%) had severe COVID-19 disease, while 8 (35%) had critical or critical with multiorgan dysfunction. Median time of follow up was 26 (range, 7–79) days. Overall, 11 (48%) survived to discharge, 6 (26%)